Novo Nordisk: positive results for semaglutide
(CercleFinance.com) - Novo Nordisk today announced the results of a Phase 3 trial showing that, compared with placebo, once-weekly semaglutide 2.
4 mg significantly reduced heart failure symptoms and led to greater weight loss in adults with heart failure with preserved ejection fraction (HFpEF) and obesity.
Clinicians have limited treatment options to offer patients living with HFpEF and obesity. Yet this is a disease that seriously affects patients' daily experience, due to debilitating symptoms and functional limitations, a lead investigator of the study said.
Copyright (c) 2023 CercleFinance.com. All rights reserved.